hepatology

News

Roche has introduced what it says is the first comprehensive panel of certified algorithms to help manage people living with chronic liver disease.

News

At its second attempt, Gilead has won FDA approval for chronic hepatitis D virus drug Hepcludex, four years after it was cleared in the EU.

News

Already sitting on a blockbuster therapy for MASH, Madrigal has beefed up its pipeline with six siRNA candidates licensed from China's Ribo.

News

A hole has been blown in Bausch Health's late-stage pipeline, after a follow-up to its top-selling drug product Xifaxan failed two phase 3 trials.

News

Madrigal Pharma is reheating a drug for metabolic dysfunction-associated steatohepatitis (MASH) put on ice by Pfizer last year.

News

Novo Nordisk has agreed to buy Akero and its MASH drug efruxifermin for $4.7bn upfront, soon after Wegovy was approved for the common liver disease.